HB002.1T + gemcitabine + cisplatin

HB002.1T + gemcitabine + cisplatin is an investigational **triple combination regimen** composed of HB002.1T, a recombinant human VEGF receptor-1 (VEGFR-1) domain 2-IgG Fc fusion protein, plus the chemotherapeutic agents gemcitabine and cisplatin. **HB002.1T acts as a decoy receptor** by binding VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby **inhibiting VEGF-mediated angiogenesis** required for tumor growth[1][3][5][7]. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based compound inducing DNA cross-linking and apoptosis. The combination has shown preliminary antitumor activity and acceptable safety in early-phase trials for advanced solid tumors, notably in ovarian, cervical, pancreatic, gallbladder, and bile duct cancers[1][3][7].